Clinicopathological findings of pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasms – compared with ductal adenocarcinoma

Pancreatology ◽  
2016 ◽  
Vol 16 (4) ◽  
pp. S119
Author(s):  
Takashi Hamada ◽  
Kana Hattori ◽  
Ken Ichikawa ◽  
Tomoki Kusafuka ◽  
Kazuhisa Fujinaga ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Mucinous Neoplasms ◽  
Clinicopathological Findings

scholarly journals Development of Pancreatic Ductal Adenocarcinoma Associated with Intraductal Papillary Mucinous Neoplasia

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Kazuo Inui ◽  
Junji Yoshino ◽  
Hironao Miyoshi ◽  
Takashi Kobayashi ◽  
Satoshi Yamamoto
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Magnetic Resonance Cholangiopancreatography ◽  
Ductal Adenocarcinoma ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Cancer Occurrence ◽  
Remnant Pancreas ◽  
Mucinous Neoplasms ◽  
Group 2 ◽  
Enhanced Computed Tomography ◽  
Periodic Evaluation

We retrospectively investigated the incidence of pancreatic ductal adenocarcinoma among patients with intraductal papillary mucinous neoplasms of the pancreas. Based on imaging in 195 such patients, we chose surgery as initial treatment for 54, and periodic evaluation over 6 to 192 months (mean, 52) for 141. In 6 of the 141 patients observed for intraductal papillary mucinous neoplasm (4.2%), pancreatic ductal adenocarcinoma developed. Further, careful monitoring for cancer occurrence in the remnant pancreas proved essential in the surgical resection group; 2 of 26 patients (7.7%) subsequently developed pancreatic ductal adenocarcinoma in the remnant pancreas, at 41 months and 137 months after surgery. Serial observation of patients with intraductal papillary mucinous neoplasms by contrast-enhanced computed tomography or magnetic resonance cholangiopancreatography therefore is critical, whether or not surgical treatment initially was performed.

scholarly journals Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review of Clinical-Pathological Features, Outcomes, and Molecular Insights

2021 ◽  
Vol 22 (13) ◽  
pp. 6756
Author(s):  
Léo Mas ◽  
Renato M. Lupinacci ◽  
Jérôme Cros ◽  
Jean-Baptiste Bachet ◽  
Florence Coulet ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Mucinous Carcinoma ◽  
Ductal Adenocarcinoma ◽  
Future Research ◽  
Pathological Features ◽  
Molecular Processes ◽  
Research Strategies ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Mucinous Neoplasms ◽  
Gnas Gene

Intraductal papillary mucinous neoplasms (IPMN) are common and one of the main precursor lesions of pancreatic ductal adenocarcinoma (PDAC). PDAC derived from an IPMN is called intraductal papillary mucinous carcinoma (IPMC) and defines a subgroup of patients with ill-defined specificities. As compared to conventional PDAC, IPMCs have been associated to clinical particularities and favorable pathological features, as well as debated outcomes. However, IPMNs and IPMCs include distinct subtypes of precursor (gastric, pancreato-biliary, intestinal) and invasive (tubular, colloid) lesions, also associated to specific characteristics. Notably, consistent data have shown intestinal IPMNs and associated colloid carcinomas, defining the “intestinal pathway”, to be associated with less aggressive features. Genomic specificities have also been uncovered, such as mutations of the GNAS gene, and recent data provide more insights into the mechanisms involved in IPMCs carcinogenesis. This review synthetizes available data on clinical-pathological features and outcomes associated with IPMCs and their subtypes. We also describe known genomic hallmarks of these lesions and summarize the latest data about molecular processes involved in IPMNs initiation and progression to IPMCs. Finally, potential implications for clinical practice and future research strategies are discussed.

scholarly journals Advances in Early Detection of Pancreatic Cancer

Diagnostics ◽  
2019 ◽  
Vol 9 (1) ◽  
pp. 18 ◽  
Author(s):  
Atsushi Kanno ◽  
Atsushi Masamune ◽  
Keiji Hanada ◽  
Masataka Kikuyama ◽  
Masayuki Kitano
Keyword(s):  
Pancreatic Cancer ◽  
Early Detection ◽  
Early Diagnosis ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Early Stage ◽  
Epidemiological Data ◽  
The United States ◽  
Ductal Adenocarcinoma ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Mucinous Neoplasms

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease. PDAC is the fourth leading cause of death in the United States and Japan based on epidemiological data. Early detection of PDAC is very important to improve the prognosis of PDAC. Early detection of pancreatic ductal adenocarcinoma (PDAC) requires further examination after selecting cases with risk factors for the condition, such as family history, hereditary pancreatic carcinoma syndrome, intraductal papillary mucinous neoplasms, or chronic pancreatitis. The Japan Study Group on the Early Detection of Pancreatic Cancer has investigated and clarified the clinicopathological features for the early diagnosis of PDAC. In Japan, an algorithm for the early diagnosis of PDAC, which utilized the cooperation of local clinics and regional general hospitals, has been a breakthrough in the detection of early-stage PDAC. Further approaches for the early diagnosis of PDAC are warranted.

Sign in / Sign up

Export Citation Format

Share Document